Brief: Altos Biologics Completes Patient Enrollment In Global Phase 3 Clinical Trial Of Eylea
22/02/2023 14:25
Feb 22 (Reuters) - Alteogen Inc 196170.KQ :
* ALTOS BIOLOGICS, A SUBSIDIARY OF ALTEOGEN, COMPLETED
PATIENT
ENROLLMENT IN GLOBAL PHASE 3 CLINICAL TRIAL OF EYLEA® BIOSIMILAR
IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Source text for Eikon: ID:nPn430Xjya
Further company coverage: 196170.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alteogen
See all newsDeals of the day-Mergers and acquisitions
Novartis signs deal worth up to $3.2 billion for Alteogen's drug delivery technology
Brief: Alteogen To Invest 253 Billion Won In Construction Of New Factory
Brief: Alteogen Q2 Operating. Profit 34.2 Billion Won
Brief: Alteogen - Signs Exclusive License Agreement For Alt-B4 Recombinant Human Hyaluronidase